Neurocrine Biosciences Inc. (NASDAQ:NBIX) does about 806.35K shares in volume on a normal day but saw 847325 shares change hands in Friday trading. The company now has a market cap of 10.08B USD. Its current market price is $103.54, marking an increase of 0.73% compared to the previous close of $102.79. The 52 week high reached by this stock is $129.29 whilst the lowest price level in 52 weeks is $75.25. The script in recent trading has seen the stock touch a high of $103.55 and a low of $101.26.
Neurocrine Biosciences Inc. (NBIX) has a 20-day trading average at $106.39 and the current price is -19.92% off the 52-week high compared with 37.59% distance from its 52-week low. The 50-day simple moving average of the closing price is $112.56 and its 200-day simple moving average is $105.46. If we look at the stock’s price movements over the week, volatility stands at 2.04%, which increases to 2.71% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 37.40 to suggest the stock is neutral.
28 analysts observing the Neurocrine Biosciences Inc. (NBIX) stock have set the 12-month price targets for the company’s shares at between $93.00 and $150.00. The consensus objective for the share price is $126.92, suggesting that the stock has a potential upside of 18.42% over the period. The median price target is 20.35% away from the current levels at $130.00.
FactSet Research has provided data showing that 28 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 3 advise that it is a overweight. 14 analysts have rated it as a buy and 10 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 03, 2023 when Morgan Stanley upgraded the stock to “Overweight” and issued a price target of between $120 and $130. Evercore ISI downgraded the stock to “In-line” from Outperform on November 14, 2022 at a price target of $140-$130. UBS initiated its price target at $136.
The current price level is -3.04%, -8.28%, and -1.75% away from its SMA20, SMA50, and SMA200 respectively, with the NBIX price moving above the 50-day SMA on February 17. Neurocrine Biosciences Inc. (NBIX) stock is up 0.34% over the week and -5.85% over the past month. Its price is -13.31% year-to-date and 20.58% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2022, with the company’s earnings per share (EPS) of $0.88 below consensus estimates by -$0.27. The company’s next earnings report is expected on 05/01/2023, with forecasts estimating quarterly EPS at $0.37 and $2.86 for whole year. NBIX’s earnings per share are forecast to grow by 83.30% this year and 64.70% over next year. Expected sales for next quarter are $444.65 million, which analysts say will come at $1.81 billion for the current fiscal year and next year at $2.11 billion. In addition, estimates put the company’s current quarterly revenue at an average of $409.88 million.
Its 12-month price target is $130.00. To reach the target analysts have set, the stock logically needs to grow 18.42 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $93.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $150.00.
Outstanding shares total 96.40M with insiders holding 0.97% of the shares and institutional holders owning 97.17% of the company’s common stock. The company has a return on investment of 6.40% and return on equity of 10.20%. The price to earnings ratio (P/E ratio) amounts to 67.19 while the forward price to earnings ratio is 21.68. The beta has a value of 0.48. Price to book ratio is 5.84 and price to sales ratio is 6.77.
According to a U.S. Securities and Exchange Commission filing, iShares Core S&P Mid Cap ETF has reduced its position in Neurocrine Biosciences Inc. (NBIX) to 2,988,052 shares, mirroring a recent drop by -0.19%. iShares Core S&P Mid Cap ETF dumped 5660.0 shares of Neurocrine Biosciences Inc. common stock bringing its total worth to about $331.46 million at the end of recent close, SEC documents show. iShares Core S&P Mid Cap ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 20019.0 shares to end up with 2,946,685 shares worth $326.88 million. BB Biotech AG cut their holdings by -7.20% in the company over the course of the most recent quarter. It now holds a 2.91% position in Neurocrine Biosciences Inc. thanks to 2.8 million shares amounting to $310.43 million.
